CA3041016C - Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles - Google Patents

Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles Download PDF

Info

Publication number
CA3041016C
CA3041016C CA3041016A CA3041016A CA3041016C CA 3041016 C CA3041016 C CA 3041016C CA 3041016 A CA3041016 A CA 3041016A CA 3041016 A CA3041016 A CA 3041016A CA 3041016 C CA3041016 C CA 3041016C
Authority
CA
Canada
Prior art keywords
estetrol
component
dysmenorrhea
estetrol component
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3041016A
Other languages
English (en)
Other versions
CA3041016A1 (fr
Inventor
Maud JOST
Glwadys RAUSIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Estetra SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra SRL filed Critical Estetra SRL
Priority to CA3178291A priority Critical patent/CA3178291A1/fr
Publication of CA3041016A1 publication Critical patent/CA3041016A1/fr
Application granted granted Critical
Publication of CA3041016C publication Critical patent/CA3041016C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de prise en charge de la dysménorrhée, consistant à administrer un composant strogénique qui est de préférence sélectionné dans le groupe constitué par l'estétrol et des composés de type estétrol. Étonnamment, les composés de type estétrol se sont révélés aptes à atténuer la dysménorrhée, lorsqu'ils sont utilisés seuls ou combinés à des composés progestatifs, dans une mesure qui dépasse l'effet obtenu avec d'autres compositions, et avec un profil d'effets secondaires avantageux par rapport aux méthodes actuellement disponibles.
CA3041016A 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles Active CA3041016C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3178291A CA3178291A1 (fr) 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/076104 WO2018065076A1 (fr) 2016-10-28 2016-10-28 Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3178291A Division CA3178291A1 (fr) 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles

Publications (2)

Publication Number Publication Date
CA3041016A1 CA3041016A1 (fr) 2018-04-12
CA3041016C true CA3041016C (fr) 2023-09-05

Family

ID=57209484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3041016A Active CA3041016C (fr) 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles

Country Status (6)

Country Link
JP (1) JP2018533542A (fr)
KR (1) KR102780201B1 (fr)
AU (1) AU2016425935B2 (fr)
CA (1) CA3041016C (fr)
MY (1) MY205032A (fr)
WO (1) WO2018065076A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
SG11202007163WA (en) 2018-02-07 2020-08-28 Estetra Sprl Contraceptive composition with reduced cardiovascular effects
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
IT202000003964A1 (it) * 2020-02-26 2021-08-26 Umberto Cornelli Composizione farmaceutica per l’uso nel trattamento di dismenorrea e/o sindrome premestruale
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022166599A1 (fr) * 2021-02-02 2022-08-11 广州沪同有梧生物科技有限公司 Nouvelle utilisation de pqq et de son dérivé
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO2012055840A1 (fr) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels
KR102712911B1 (ko) * 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Also Published As

Publication number Publication date
CA3041016A1 (fr) 2018-04-12
KR20190076014A (ko) 2019-07-01
JP2018533542A (ja) 2018-11-15
KR102780201B1 (ko) 2025-03-12
MY205032A (en) 2024-09-28
AU2016425935B2 (en) 2023-01-19
WO2018065076A1 (fr) 2018-04-12
AU2016425935A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
AU2022231672B2 (en) Method for the management of dysmenorrhea and menstrual pain
CA3041016C (fr) Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
US20250360147A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
RU2169567C2 (ru) Способ контрацепции женщин репродуктивного возраста, не достигших предменопаузы
KR101812160B1 (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
NZ262657A (en) Hormone replacement therapy using estrogen and antiprogestin
IL187471A (en) Quadraphasic continuous graduated estrogen contraceptive
EP1796725B1 (fr) Traitement ou prevention des hemorragies occasionnelles chez les femmes sous progestogenotherapie
Von Schoultz Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment
JP2008527018A (ja) 避妊用医薬製剤
JPH08508502A (ja) 骨粗しょう症の治療方法および治療用組成物
US20080280861A1 (en) Method of Female Contraception and a Kit For Use Therein
Contraception Section 4 Contraception

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210504

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241028

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250110

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251015

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251015